BioRobotics Aquablation® Robotic Benign Prostatic Hyperplasia (BPH) System AB2000 - Robotics Medical Equipment

Save 20% on the Procept Aquablation® AB2000 and accessories when purchased through NHS Supply Chain.

Aquablation® robotic BPH technology is an advanced, minimally invasive surgical treatment for BPH. Combining the precision of robotics with the power of a heat-free water jet, it allows surgeons to remove excess prostate tissue safely, consistently, and with reduced risk of complications compared to traditional methods.

Designed to deliver predictable outcomes across a broad range of prostate sizes. Aquablation® is redefining BPH care within the NHS.

Special offer for NHS Supply Chain with a 20% saving on the robotic capital and accessories of the Aquablation® robotic BPH technology.

• Real-time imaging with robotic guidance – uses ultrasound and robotic technology to map and remove prostate tissue with millimetre precision, reducing errors and improving outcomes.
• Heat-free water jet ablation – removes tissue using a high-speed water jet instead of heat, lowering the risk of thermal damage to surrounding structures.
• Customisable treatment plans – enables surgeons to adapt the procedure to each patient’s anatomy and prostate size, from small to very large glands.
• Consistent, automated outcomes – robotic execution reduces variability between surgeons, ensuring predictable and reproducible results.
• Enhanced visualisation – combines cystoscopic and ultrasound imaging for clear, real-time guidance during the procedure.
• Preserves sexual function – lower risk of complications such as retrograde ejaculation compared to traditional surgical methods.
• Suitable for a wide range of patients – effective for all prostate sizes, including very large glands where other options may be limited.
• Shorter learning curve for surgeons – robotic precision simplifies complex resections, making the technique accessible to more urologists.
• Improved safety profile – heat-free technology reduces risks of urethral strictures, sphincter damage, and incontinence.
• Efficiency and cost savings – standardised treatment times and ability to treat any prostate size allow more patients per theatre list, with up to 80% moved to day-case surgery—reducing bed occupancy and overall costs.

This offer is over and above the standard discount available through the NHS Supply Chain framework agreement. The discount is a fixed term offer. All orders must be placed before 31 December 2025.